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Abstract
In an earlier study, we reported that chronic ethanol (EtOH) stimulates the formation of anandamide in human SK-N-SH
cells. In the present study, we investigated the effect of chronic EtOH on the formation of yet another cannabinoid receptor
(CB1) agonist, 2-arachidonylglycerol (2-AG), in cerebellar granule neurons (CGNs). The formation of 2-[3H]AG without any
stimulation was more pronounced in the older cultures than in younger cultures. Exposure of CGNs to EtOH led to a
significant increase in the level of 2-[3H]AG (P6 0.05). Incubation with the anandamidehydrolase inhibitor phenylmethyl-
sulfonyl fluoride and EtOH did result in an additive increase in 2-[3H]AG, but did not with E-6-(bromomethylene)tetrahy-
dro-3-(1-naphthelenyl)-2H-pyran-2-one. The formation of 2-[3H]AG was enhanced by ionomycin in both the control and
EtOH-exposed CGNs, and the ionomycin-stimulated 2-[3H]AG synthesis was inhibited by the intracellular chelating agent
1,2-bis(2-aminophenoxy)ethane-N,N,NP,NP-tetraacetic acid. Further, glutamate increased the formation of 2-[3H]AG only in
control CGNs. MK-801 inhibited the EtOH-induced 2-[3H]AG synthesis, suggesting the participation of intracellular Ca2 in
EtOH-induced 2-[3H]AG synthesis. The dopamine receptor (D2) agonist did not modify the 2-AG synthesis in either the
control or EtOH-exposed CGNs. However, the D2 receptor antagonist inhibited the EtOH-induced formation of 2-[3H]AG.
The EtOH-induced 2-[3H]AG formation was inhibited by SR141716A and pertussis toxin, suggesting the CB1 receptor- and
Gi/o-protein-mediated regulation of 2-AG. The observed increase in 2-AG level in CGNs is possibly a mechanism for
neuronal adaptation to the continuous presence of EtOH. These findings indicate that some of the pharmacological actions
of EtOH may involve alterations in the endocannabinoid signaling system. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Chronic ethanol (EtOH) has been shown to a¡ect
neurobiological and neurodegenerative processes in
the brain. Although the molecular mechanisms by
which EtOH produces its pharmacological e¡ects
have not been established, recent evidence suggests
that many components of intracellular signal trans-
duction pathways, including several receptors, li-
gand-gated ion channels, and enzymes, are targets
of EtOH action in the central nervous system
(CNS) [1^4].
Cannabinoid receptors (CB1) belong to G-protein-
coupled receptors and are known to share G-proteins
and/or e¡ector molecules with other G-protein-
coupled receptors [5]. This produces biological re-
sponses by regulation of enzymes and/or ion channel
activity through selective activation of signal trans-
ducing G-proteins [6]. The only endogenous canna-
binoid substances isolated and characterized so far
that are capable of mimicking the pharmacological
actions of v9-tetrahydrocannabinol (v9-THC), the
active ingredient of marijuana, and other synthetic
agonists [7] are anandamide (AnNH) and 2-arachi-
donylglycerol (2-AG) [8^10]. Both AnNH and 2-AG
have been shown to bind speci¢cally to CB1 recep-
tors in the brain [8,9,11]. Although recent evidence
indicates the involvement of a CB1 receptor signal
transduction system in the pharmacological actions
of EtOH including voluntary EtOH consumption
[3,4,12^18], the exact molecular mechanism remains
to be established. Recently, we demonstrated that
chronic EtOH increases the formation of the CB1
receptor agonist AnNH through selective activation
of arachidonic acid-speci¢c phospholipase A2 (PLA2)
in human SK-N-SH cells and mouse brain [14,19,20].
In the present study, we examined whether or not
chronic EtOH treatment has any e¡ect on the for-
mation of yet another CB1 receptor agonist, 2-AG,
using rat cerebellar granule neurons (CGNs). We
found that chronic EtOH treatment increased the
synthesis of 2-AG in CGNs. The results also indicate
that calcium ions, CB1 receptors, and Gi/o-proteins
may regulate 2-AG levels in CGNs.
2. Materials and methods
2.1. Materials
All culture plastic supplies were purchased from
Falcon Labware (VWR Scienti¢c, Pascataway, NJ).
Basal medium Eagle’s, heat-inactivated fetal calf se-
rum (FBS), streptomycin, and penicillin solutions
were from Sigma (St. Louis, MO). Liquid scintilla-
tion cocktail (Insta-Fluor) was purchased from
Packard (Meriden, CT). Arachidonic acid (AA)
was obtained from Avanti Polar Lipids (AL). 2-
Arachidonylglycerol was purchased from Deva Bio-
tech (Hartboro, PA). ( þ )-2-Dipropylamino-7-hy-
droxy-1,2,3,4-tetrahydronaphthalene hydrobromide
(7-H-DPAT), haloperidol, and MK-801 were from
RBI (Natick, MA). E-6-(Bromomethylene)tetrahy-
dro-3-(1-naphthelenyl)-2H-pyran-2-one (BTNP) was
from Biomol (Plymouth Meeting, PA). SR141716A
was a kind gift from Sano¢ Pharmaceuticals (Mont-
pellier, France). [3H]Arachidonic acid (200 Ci/mmol)
was purchased from American Radiolabeled Chem-
icals (St. Louis, MO). All other chemicals were ob-
tained from Sigma (St. Louis, MO).
2.2. Primary cultures of cerebellar granule neurons
Cerebellar granule neuronal primary cultures were
prepared from dissociated cerebella of 8-day-old
Sprague-Dawley rat pups, as described previously
[21]. Brie£y, cells were counted, and approx. 8U106
cells were plated on a polylysine-coated 100 mm cul-
ture dish with 8 ml of BEM (basal medium Eagle’s,
Sigma) supplemented with 10% fetal calf serum
(FCS), 25 mM KCl, 200 mM glutamine, 10 000 units
penicillin, and 10 mg streptomycin. Cells were main-
tained at 37‡C in a 95% air/5% CO2 incubator. Cy-
tosine-L-D-arabinofuranoside (10 WM) (Sigma) was
added to the culture medium 18^22 h after plating.
After 7 days in vitro (DIV), the cells were used for
experiments. In some experiments 2 DIV CGNs were
used.
2.3. Incubations
The cells were incubated with [3H]arachidonic acid
(AA) (1 WCi/ml) in BEM (without FCS) for 5 h. The
medium was monitored for uptake and it was found
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that 85% of the total AA was incorporated into the
cells within 5 h of incubation. The cells were then
washed three times with 0.1% BSA:BEM to remove
essentially all the free AA. The cells were then re-
plenished with the old conditioned medium (5 ml)
and then subjected to EtOH exposure. The culture
conditions were similar to the ones described by
others and us for chronic EtOH investigations
[14,22]. EtOH levels (50, 100, 150 mM) were main-
tained by adding appropriate concentrations of ab-
solute alcohol. All dishes were £ushed with 5% CO2-
95% air and sealed with para¢lm before incubation.
The medium was then supplemented at 24 and 48 h
with absolute EtOH (4 Wl/5 ml for 50 mM; 25 Wl/5 ml
for 100 mM; 30 Wl/5 ml for 150 mM). EtOH level in
the medium at 72 h was determined by an enzymatic
method [23] (50 þ 1.0 mM; 100 þ 6.0 mM; 150 þ 17.0
mM, n = 6). Appropriate control cultures were simi-
larly maintained in a medium containing no EtOH.
The cultures were incubated in BEM containing
drugs at the indicated concentrations. Ionomycin
(1^10 WM), phenylmethylsulfonyl £uoride (PMSF)
(10 WM), and SR141716A (1^10 WM) were added
from stock solutions in dimethyl sulfoxide
(DMSO). Final concentration of DMSO never ex-
ceeded 0.2%, and this concentration had no e¡ect
on cell viability. For treatment with various agents,
culture plates were co-treated with PMSF (50 WM) or
BTNP (10 WM) or glutamate (10 WM) or MK-801 (10
WM) or 7-H-DPAT (1 WM) or haloperidol (1 WM) or
SR141716A (1 WM) or pertussis toxin (PTX) (100
ng/ml) and with or without EtOH. For Ca2 iono-
phore ionomycin treatment, neurons, with or without
being ¢rst exposed to EtOH (100 mM, 72 h), were
exposed to ionomycin (1^10 WM) with or without
1,2-bis(2-aminophenoxy)ethane-N,N,NP,NP-tetraace-
tic acid (BAPTA-AM) (30 WM) for 10 min. Cells
were examined for viability by trypan blue exclusion
and counted. The incubations were terminated by
collecting the medium. The cells were scraped and
then suspended in 10 mM Tris-HCl bu¡er pH 7.4
containing protease inhibitor cocktail (Sigma). Data
(medium and cells) are expressed as the (mean þ
S.E.M.) dpm/mg cellular protein or % of control.
2.4. Extraction and chromatography
Lipids from cells and medium were extracted using
a mixture of chloroform/methanol (2:1, v/v) [24], 2
Wg of unlabeled 2-AG was included as a carrier. Bu-
tylated hydroxytoluene (BHT) (0.05%) was added to
prevent lipid peroxidation. The dried extracts were
redissolved in a mixture of chloroform/methanol
(2:1, v/v), spotted onto TLC plates (silica gel 60,
250 Wm thickness), and developed with one of the
following solvent systems: the organic phase of a
mixture of isooctane/ethyl acetate/water/acetic acid
(50:110:100:30, v/v) (solvent system A), which al-
lows the separation of 2-AG (RF = 0.53) from
N-arachidonylphosphatidylethanolamine (N-ArPE)
(RF = 0.14), AnNH (RF = 0.43) and AA (RF = 0.78);
chloroform/methanol/acetic acid (85:15:1, v/v) (sol-
vent system B), which allows separation of N-ArPE
(RF = 0.35) from AnNH (RF = 0.7) and AA+2-AG
(RF = 0.9); diethyl ether/petroleum ether/NH4OH
(50:50:1, v/v) (solvent system C), which allows sep-
aration of AA (RF = 0.0) and 2-AG (RF = 0.2). The
band corresponding to authentic 2-AG was scraped
o¡ the plate into scintillation vials containing 1 ml of
chloroform/methanol (2:1). The radioactivity was de-
termined using 10 ml of scintillation liquid (Insta-
Fluor, Packard). In a separate experiment, the lipids
were extracted from the medium and the cells (12
plates) and were subjected to TLC puri¢cation. The
identity of 2-AG was con¢rmed by scraping the band
corresponding to authentic 2-AG and gas chroma-
tography-MS (GC-MS) analysis of trimethylsilyl
ether (TMS) derivatives. In brief, the isolated 2-AG
fraction was treated with 60 Wl of TMS reagent (All-
tech Associates, Deer¢eld, IL) at 80‡C for 1 h
[25,26]. The TMS derivative was then injected di-
rectly into the GC-MS. The GC-MS was performed
on a Hewlett Packard 5988 mass spectrometer
equipped with 5890 series GC and a 7673 automatic
injector. The capillary column (HP5MS, 30 mU0.25
mm i.d.) was temperature-programmed from 90 to
270‡C at 10‡C/min. The mass spectrometer was op-
erated in the electron impact (EI) (70 eV) mode and
the electron impact mass spectra of the TMS deriv-
ative of both the synthetic and tissue-derived 2-AG
were compared.
2.5. Protein determination
Protein concentration of the cell homogenates was
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determined by the Lowry procedure using bovine
serum albumin as the standard [27].
2.6. Statistical analysis
Statistical analysis was performed by Student’s
t-test and one-way analysis of variance (ANOVA)
followed by Dunnett’s test using the Graphpad Prism
version 2.01 software program (Graphpad Software,
San Diego, CA). Di¡erences were considered to be
signi¢cant if P6 0.05. Data are presented as means
þ S.E.M. from at least three separate experiments
run in triplicate.
3. Results
The identity of 2-AG extracted from the cells and
medium was con¢rmed by comparison of RF values
with those of the authentic 2-AG after separation in
three di¡erent solvent systems. Further characteriza-
tion of 2-AG was achieved by GC-MS analysis of the
TMS derivative of TLC-puri¢ed 2-AG. Diagnostic
ions for 2-AG included m/z 522 (M, molecular
ion), 507 [M-15], loss of methyl radical, 451
[M-71], loss of pentyl radical and 432 [M-90],
loss of trimethyl silenol (data not shown).
It is observed that the formation of 2-[3H]AG
in unstimulated CGNs in culture was found to be
age-dependent (DIV) (Fig. 1). The formation of
2-[3H]AG was more pronounced in the older cultures
(7^8 DIV) than in younger cultures (3^5 DIV).
Therefore, the 7 DIV cultures were employed for
further studies.
Neurons (CGNs) were exposed to various concen-
trations of EtOH (50, 100, and 150 mM for 72 h)
and also 100 mM EtOH for various times (24, 48 and
72 h). The cell viability was una¡ected irrespective of
the treatment conditions employed as determined by
the trypan blue exclusion method (data not shown).
We investigated the e¡ect of EtOH on 2-[3H]AG
formation using CGNs prelabeled with [3H]AA.
Treatment with EtOH caused a time-dependent in-
crease in the formation of 2-[3H]AG (Fig. 2A,B). The
Fig. 1. Formation of 2-[3H]AG in CG neurons as a function of
days in vitro. Cells were labeled with [3H]AA (1 WCi/ml) at
2 DIV in BME (without FCS) for 5 h and then incubated as
described in Section 2. The 2-[3H]AG was extracted from me-
dium and cells and separated on TLC using solvent system A
and the results are expressed as dpm/mg cellular protein. Each
value represents the mean þ S.E.M. (n = 6).
Fig. 2. Formation of 2-[3H]AG in CG neurons following expo-
sure to various concentrations of EtOH (A) and for various
times (B). Cells (7 DIV) were labeled with [3H]AA (1 WCi/ml)
in BME (without FCS) for 5 h and then exposed to various
concentrations of EtOH for 72 h or for various times at 100
mM EtOH as described in Section 2. The 2-[3H]AG was ex-
tracted from medium and cells and separated on TLC using
solvent system A. Values for basal control are similar to those
in Fig. 1 and in panel A. Each value represents the mean þ
S.E.M. (n = 9). *P6 0.05 (Student’s t-test), compared with con-
trol.
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results also indicated that EtOH treatment of CGNs
did not have any signi¢cant e¡ect on the level of
2-[3H]AG at 50 mM for 72 h (Ps 0.05), but pro-
duced a statistically signi¢cant increase at 100 and
150 mM for 72 h (P6 0.05). Exposure of CGNs to
EtOH (100 mM) gradually increased the level of
2-[3H]AG, reaching a statistically signi¢cant level
after 24, 48, and 72 h (P6 0.05). Most of the syn-
thesized 2-[3H]AG was released from the cells and
found in the medium (85%) at 72 h (data not shown).
The data are shown as the total (medium plus cells)
(Fig. 2A,B).
In order to determine the possible mechanism of
EtOH-induced formation of 2-[3H]AG, CGNs were
treated with various neuromodulators that are sug-
gested to modulate the endocannabinoid system
[28,29].
A higher level of 2-[3H]AG (2.45 fold; P6 0.05)
was observed when CGNs were co-treated with
EtOH (100 mM; 72 h) and PMSF (50 WM), an ami-
dohydrolase inhibitor known to inhibit 2-[3H]AG hy-
drolysis [30] (Table 1), whereas bromoenol lactone,
BTNP (10 WM), a potent inhibitor of amidohydro-
lase, had no e¡ect (Ps 0.05). Incubation of cells with
PMSF (50 WM) or BTNP (10 WM) produced no cell
death and no lifting of the cell monolayer.
Table 1 shows the e¡ect of glutamate and MK-
801, an NMDA receptor antagonist, on EtOH-in-
duced formation of 2-[3H]AG in CGNs. It was found
that glutamate enhances the formation of 2-[3H]AG
only in control cells (1.6-fold; P6 0.05) and has no
additive e¡ect when CGNs were co-treated with
EtOH (100 mM, 72 h) (Ps 0.05). However, when
CGNs were co-treated with MK-801 (10 WM) and
EtOH (100 mM) for 72 h, a signi¢cant inhibition
of EtOH-induced formation of 2-[3H]AG (27%;
P6 0.05) was observed, and this inhibition was not
observed in control cells (Ps 0.05) (Table 1). Fur-
ther, when CGNs were co-treated (72 h) with dop-
amine receptor (D2) agonist (7-H-DPAT, 1 WM) and
Table 1
E¡ect of various neuromodulators on the formation of
2-[3H]AG in CGNs following co-exposure to 100 mM EtOH
for 72 h
Neuromodulators Control Ethanol
Basal 100.00 þ 14.50 165.70 þ 20.73* (a)
PMSF (50 WM) 245.90 þ 59.93* (c) 242.10 þ 14.10* (c, b)
BTNP (10 WM) 125.20 þ 16.06 156.90 þ 13.80* (a, c)
Glutamate (10 WM) 159.80 þ 11.68* (c) 166.10 þ 19.10* (c)
MK-801 (10 WM) 133.60 þ 10.86 120.40 þ 01.10* (b)
7-H-DPAT (1 WM) 109.60 þ 18.23 158.10 þ 19.23* (c)
Haloperidol (1 WM) 125.10 þ 11.73 107.90 þ 15.10* (b)
Cells were labeled with [3H]AA (1 WCi/ml) in BME (without
FCS) for 5 h and then co-treated with PMSF (50 WM), BTNP
(10 WM), glutamate (10 WM), MK-801 (10 WM), 7-H-DPAT (1
WM), haloperidol (1 WM) and with or without EtOH as de-
scribed in Section 2. The 2-[3H]AG was extracted from medium
and cells and separated on TLC, system A. Values for basal
control are similar to those in Figs. 1 and 2. Each value repre-
sents the mean þ S.E.M. (n = 9). *P6 0.05 (ANOVA); (a), ver-
sus respective control ; (b), versus basal EtOH; (c), versus basal
control.
Fig. 3. E¡ect of ionomycin (A) on chronic EtOH-induced for-
mation of 2-[3H]AG or e¡ect of BAPTA-AM (B) on the iono-
mycin-induced formation of 2-[3H]AG in chronic EtOH-exposed
CGNs. Cells were labeled with [3H]AA (1 WCi/ml) in BME
(without FCS) for 5 h and exposed to EtOH (100 mM, 72 h)
and then treated with or without various concentrations of ion-
omycin or ionomycin (10 WM) with or without BAPTA-AM
(30 WM) for 10 min as described in Section 2. The 2-[3H]AG
was extracted from medium and cells and separated on TLC,
system A. Values for basal control are similar to those in Figs.
1 and 2. Each value represents the mean þ S.E.M. (n = 9).
*P6 0.05 (ANOVA); a, versus respective control; b, versus
basal EtOH; c, versus basal control; d, versus ionomycin con-
trol; e, versus ionomycin EtOH.
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EtOH (100 mM), no signi¢cant e¡ect on the EtOH-
induced formation of 2-AG was observed (Ps 0.05)
(Table 1). However, the treatment with dopamine
receptor antagonist (haloperidol, 1 WM) and EtOH
(100 mM) inhibited the EtOH-induced formation of
2-AG signi¢cantly (35%; P6 0.05) (Table 1).
When chronic EtOH-exposed CGNs (100 mM; 72
h) were treated with various concentrations of iono-
mycin (0^10 WM) for 10 min, in addition having
dose-dependent stimulatory action on control
CGNs, ionomycin was found to be potent in enhanc-
ing EtOH-induced formation of 2-[3H]AG (Fig. 3A)
at 2.5 WM, 5 WM and there was no signi¢cant di¡er-
ence between 5 WM and 10 WM ionomycin. Further-
more, when chronic EtOH-exposed CGNs were co-
treated with ionomycin (10 WM) and BAPTA-AM
(10 WM), an intracellular Ca2 chelator, for 10 min,
the result was an inhibition of ionomycin-stimulated
2-[3H]AG formation both in control and EtOH-ex-
posed cells (Fig. 3B).
We studied the e¡ect of the CB1 receptor antago-
nist SR141716A and pertussis toxin to determine fur-
ther whether EtOH-induced formation of 2-[3H]AG
in CGNs is receptor/G-protein mediated. Co-treat-
ment of CGNs with various concentrations of CB1 receptor antagonist SR141716A (0^10 WM) and
EtOH (100 mM) for 72 h blocked (100%; P6 0.05)
the EtOH-induced formation of 2-[3H]AG at lower
concentration (1 WM) but at higher concentrations it
increased the formation of 2-[3H]AG in a dose-de-
pendent manner in both control and EtOH-treated
cells (P6 0.05) (Fig. 4). Co-exposure of CGNs to
pertussis toxin (100 ng/ml) and EtOH (100 mM)
for 72 h resulted in an inhibition of EtOH-induced
formation of 2-[3H]AG (100%) (Fig. 5).
4. Discussion
Recently, a second phospholipid-derived messen-
ger, 2-AG, has been identi¢ed and reported to dis-
play properties of an endogenous cannabinoid recep-
tor agonist [9,10,31]. The CGNs could start synthesis
of 2-AG as early as 3 DIV and further increase with
the age of the culture. Although the physiological
roles of 2-AG in normal brain cells and tissue is
not clear, a substantial amount of 2-AG has been
detected in normal rat brain and cortical neurons
[32,33]. 2-AG may have a role in lipid remodeling
Fig. 4. E¡ect of CB1 receptor antagonist SR141716A on the
formation of 2-[3H]AG in CGNs following exposure to 100
mM EtOH for 72 h. Cells were labeled with [3H]AA (1 WCi/ml)
in BME (without FCS) for 5 h and then treated with various
concentrations of SR141716A (1^10 WM) and with or without
EtOH as described in Section 2. The 2-[3H]AG was extracted
from medium and cells and separated on TLC, system A. Val-
ues for basal control are similar to those in Figs. 1 and 2. Each
value represents the mean þ S.E.M. (n = 9). *P6 0.05 (AN-
OVA); a, versus respective control; b, versus basal EtOH;
c, versus basal control.
Fig. 5. E¡ect of PTX on the formation of 2-[3H]AG in CGNs
following exposure to 100 mM EtOH for 72 h. Cells were la-
beled with [3H]AA (1 WCi/ml) in BME (without FCS) for 5 h
and then co-treated with PTX (100 ng/ml) and with or without
EtOH as described in Section 2. The 2-[3H]AG was extracted
from medium and cells and separated on TLC, system A. Val-
ues for basal control are similar to those in Figs. 1 and 2. Each
value represents the mean þ S.E.M. (n = 9). *P6 0.05 (AN-
OVA); a, versus respective control; b, versus basal EtOH.
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leading to increases in cellular diglyceride levels that
in turn are important receptor-coupled signaling
molecules. To our knowledge, this study represents
the ¢rst examination of chronic EtOH-stimulated
2-[3H]AG formation in CGNs. Previously, we dem-
onstrated that chronic EtOH exposure increased the
synthesis of CB1 receptor agonist AnNH and its pre-
cursor, N-ArPE in SK-N-SH cells. It was shown that
chronic EtOH downregulates the CB1 receptor num-
ber and function [3,4] in mouse brain. Distinct di¡er-
ences in the CB1 receptor binding in the brain of two
inbred strains of mice shown to di¡er in their pref-
erence for EtOH have also been demonstrated [17].
Furthermore, the inhibition of EtOH intake by the
CB1 receptor antagonist SR141716A in rats [13] and
mice [12] has been reported. These results, taken to-
gether, point to an important role for the endocan-
nabinoid signaling system in the pharmacological ac-
tions of EtOH.
Similar to AnNH synthesis in SK-N-SH cells [14],
EtOH treatment of CGNs led to the enhanced for-
mation of 2-[3H]AG in a dose- and time-dependent
manner. This increase in endogenous cannabinoids,
2-AG and AnNH [14] levels following exposure to
chronic EtOH may be responsible for the downregu-
lation of CB1 receptor function in EtOH-tolerant
mice observed in our previous studies [3,4]. Recently,
such a phenomenon was also found in some brain
regions of v9-tetrahydrocannabinol-tolerant rats [34].
Although the levels of AnNH and other N-acyletha-
nolamines (NAEs) are considerably low in normal
tissues, their levels have been found to increase sig-
ni¢cantly during cell injury, tissue degeneration, and
during the post mortem period [25,35^37]. The brain
levels of 2-AG were shown to be 170 times greater
than those of AnNH [10]. Interestingly the levels of
2-AG could be enhanced by electrical high frequency
stimulation in hippocampal slices [10]. The exact
mechanism by which 2-AG is synthesized has not
been clearly established. The available evidence sug-
gests that three main biochemical pathways seem to
exist in neurons for the formation of 2-AG through
the sequential action of a PI-speci¢c phospholipase
C, sn-1-diacylglycerol lipase, and/or calcium-depen-
dent transacylation and phospholipase C
[10,28,29,38].
The majority of the EtOH-stimulated 2-AG was
found to be accumulated in the medium (85%), sug-
gesting that a signi¢cant portion of biosynthesized
2-AG is released outside neurons. These results are
comparable to analogous data obtained by stimula-
tion of 2-AG formation by ionomycin in neuroblas-
toma cells [38]. The amidohydrolase enzyme inhibi-
tor PMSF was also shown to inhibit the 2-AG
hydrolysis in neurons and was also e¡ective in en-
hancing the accumulation of 2-AG in both the con-
trol and EtOH-exposed CGNs. Conversely, 2-AG
accumulation was not a¡ected by the more selective
anandamide amidohydrolase inhibitor BTNP. These
results are in agreement with the previous observa-
tion, where BTNP (5 WM) had no e¡ect on 2-AG
accumulation or metabolism in human astrocytoma
cells [39]. Therefore, the possibility remains for the
existence of a speci¢c lipase for 2-AG hydrolysis,
which may be responsible for the physiological inac-
tivation of 2-AG in neurons and this should be in-
vestigated in future studies.
We have extended these observations with various
neuromodulators in order to elucidate the possible
mechanism by which EtOH might increase the for-
mation of 2-AG in CGNs. Treatment of chronic
EtOH-exposed CGNs with increasing doses of iono-
mycin (2.5^10 WM) for 10 min led to an increase in
the formation of 2-AG. Further, we assessed whether
ionomycin-induced 2-AG formation was Ca2-de-
pendent, and therefore stimulated the chronic
EtOH-exposed cells with ionomycin (10 WM) in the
presence or absence of the intracellular Ca2 chelat-
ing agent BAPTA-AM (30 WM). The BAPTA-AM
inhibited signi¢cantly the e¡ect of ionomycin (10
WM) on EtOH-induced formation of 2-AG (Fig.
3A,B). A similar ionophore-induced AnNH and N-
ArPE biosynthesis has been shown in various neuro-
nal cells [14,32,40,41]. It has been shown that chronic
EtOH exposure leads to an increase in intracellular
Ca2 levels in mouse brain synaptosomes [42], rat
cerebellar macroneurons [43], PC12 cells [44], and
cerebral vascular smooth muscle cells [45,46]. Based
on these data, it is suggested that, in CGNs, the
chronic EtOH-induced formation of 2-AG might be
triggered by an increase in cytoplasmic Ca2 concen-
tration.
It is interesting to note that the endocannabinoid
signal transduction system may be modulated by var-
ious other neurotransmitter systems [47], which are
shown to be involved in chronic EtOH action [2]. In
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order to establish possible interactions between the
EtOH-induced formation of 2-AG and other neuro-
transmitter systems, the e¡ect of NMDA receptor
agonist and antagonist and D2 receptor agonist
and antagonist on the EtOH-induced formation of
2-AG in CGNs was investigated. Glutamate, which
is also known to stimulate the formation of AnNH
in cortical neurons [32], stimulated the formation of
2-AG in CGNs. However, glutamate did not cause
further enhancement of the EtOH-induced formation
of 2-AG, suggesting EtOH might have caused a sat-
uration of 2-AG levels that could not be increased
further by glutamate. However, the EtOH-induced
formation of 2-AG could be inhibited by the
NMDA receptor antagonist MK-801. Interestingly,
the CGNs exhibited 100% increase in [Ca2]i after
4 days of exposure to EtOH [48], suggesting that
the glutamate-induced increase in intracellular Ca2
may be responsible for the formation of 2-AG by
CGNs. This also suggests that chronic EtOH-in-
duced activation of the NMDA receptor may trigger
an increase in cytoplasmic Ca2 concentration, which
in turn may be responsible for the enhanced synthesis
of 2-AG. The D2 receptor agonist did not enhance
the formation of 2-AG either in control or in EtOH-
exposed CGNs, whereas co-treatment of CGNs with
D2 receptor antagonist inhibited the EtOH-induced
formation of 2-AG, suggesting the interaction of D2
receptor system or direct action of this compound on
the EtOH-induced formation of 2-AG. The D2 re-
ceptor activation by the agonist quinpirole led to
eightfold stimulation of AnNH release in striatum
without a¡ecting the 2-AG release, and this stimula-
tion was inhibited by the antagonist raclopride [49].
These results suggest the possible di¡erences in the
activation and/or inhibition of D2 receptors in vari-
ous regions of the brain, which may in£uence the
formation of endocannabinoids. Further studies are
necessary to establish this phenomenon.
Previously, it has been shown that cerebellum and
cerebellar granular cells contain a high density of
CB1 receptors and receptor-activated GTP binding
proteins [50,51]. Our results with SR141716A and
PTX suggest that the level of 2-AG in chronic
EtOH-treated CGNs may be regulated by CB1 re-
ceptors and Gi/o-proteins, as observed for AnNH
biosynthesis [14]. However, EtOH-induced formation
of 2-AG was inhibited by SR141716A only at lower
concentration. At higher concentration SR141716A
was found to have a stimulatory e¡ect in CGNs
which are not exposed to EtOH, suggesting its dual
nature of action. SR141716A probably acts through
the CB1 receptor at lower concentration and at high-
er concentration it may be acting independent of this
receptor or as an inverse agonist. It is entirely possi-
ble that high concentrations of SR141716A may re-
sult in non-speci¢c e¡ects which may not necessarily
be related to CB1 receptor blockade. In fact,
SR141716A has been reported to exhibit inverse ag-
onism in vivo in causing hyperalgesia in a mouse
model of thermal pain [52]. CB1 receptor antagonist
SR141716A was shown to block voluntary EtOH
intake in rats (EtOH preferring) [13] and mice [12]
and CB1 receptor agonist CP,55,940 was shown to
increase the motivation for beer in rats [15], suggest-
ing that the endocannabinoid system may constitute
part of a common brain pathway mediating rein-
forcement of drugs of abuse including alcohol. These
results suggest a possible role for these endogenously
formed cannabinoid agonists and a signal transduc-
tion system in alcohol tolerance and dependence and
warrant further investigation.
In summary, we have found that CB1 receptor
agonist 2-AG synthesis was stimulated by chronic
EtOH in primary cultures of cerebellar granule neu-
rons, probably as a neuroadaptation mechanism in
response to the continuous presence of EtOH. The
EtOH-induced formation of 2-AG is found to be
regulated by CB1 receptors and by various neuro-
modulators.
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